Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Boehringer Ingelheim
McKinsey
Mallinckrodt
Moodys

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,752,197

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,752,197
Title:Method for detecting methylation of colorectal cancer specific methylation marker gene for colorectal cancer diagnosis
Abstract: The present invention relates to a method for detecting methylation of the bowel-cancer-specific methylation marker GPM6A (NM_201591, glycoprotein M6A) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present invention can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis.
Inventor(s): An; Sung Whan (Daejeon, KR), Oh; Tae Jeong (Daejeon, KR)
Assignee: GENOMICTREE, INC. (Daejeon, KR)
Application Number:15/010,379
Patent Claims:1. A method for detecting CpG methylation of GPM6A (glycoprotein M6A) gene, the method comprising the steps of: (a) isolating genomic DNA from a clinical sample; (b) treating the genomic DNA or a fragment thereof with bisulfite; (c) amplifying a methylated CpG of GPM6A gene in the bisulfite-treated genomic DNA or fragment thereof from step (b) by using primer(s) comprising sequence(s) selected from the group consisting of SEQ ID Nos: 24 to 69; and (d) determining whether the CpG GPM6A was methylated based on whether the DNA was amplified in step (c).

2. The method of claim 1, wherein the step (c) is performed by detecting methylated CpG of the promoter or the CpG of the first intron of GPM6A gene.

3. The method of claim 2, wherein the first intron of GPM6A gene has a sequence of SEQ ID NO: 1.

4. The method of claim 1, wherein the detection of methylation is performed by a method selected from the group consisting of PCR, methylation-specific PCR, real-time methylation-specific PCR, quantitative PCR, pyrosequencing, and bisulfite sequencing.

5. The method of claim 1, wherein the clinical sample is selected from the group consisting of a tissue, cell, blood, blood plasma, serum, feces, and urine from a patient suspected of cancer or a subject to be diagnosed.

6. The method of claim 1, further comprising using probe(s) capable of hybridizing with a methylated CpG of GPM6A comprising at least one or more CpG dinucleotide in a region which hybridizes to the methylated CpG of GPM6A.

7. The method of claim 6, wherein the probe(s) comprises sequence(s) selected from the group consisting of SEQ ID NOS: 70-92.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
South Korea10-2010-0129208Dec 16, 2010

Details for Patent 9,752,197

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial GENOMICTREE, INC. (Daejeon, KR) 2030-12-16 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial GENOMICTREE, INC. (Daejeon, KR) 2030-12-16 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial GENOMICTREE, INC. (Daejeon, KR) 2030-12-16 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Medtronic
McKinsey
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.